Company: MBIO
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001410578-25-000028
Chunk: 288

Company: MUSTANG BIO, INC.
Filing Date: 2025-01-15
Form: S-1
Chunk 288
---
                  | 0.19 |   |                 2.50 |
| Outstanding as of September 30, 2024 |   |  60,957,004 | ​ | $                | 0.29 |   |                 2.73 |

F-45

Upon the exercise of warrants, the Company will issue new shares of common stock. In connection with the Company’s Registered Direct Offering on October 26, 2023, the Company issued pre-funded warrants to purchase up to 1,668,236 shares of common stock, and in a concurrent private placement, the Company issued unregistered warrants to purchase up to 2,588,236 shares of common stock, and the resale of the underlying shares of common stock were subsequently registered in April 2024 on Form S-1 (File No. 333-275997). In connection with these offerings, H.C. Wainwright received Placement Agent Warrants to purchase up to 155,294 shares of common stock.In connection with the Public Offering the Company completed in May 2024, the 2,588,236unregistered warrants were repriced from the original exercise price of $ 1.58per share to $ 0.237per share. In connection with the May 2024 Offering, the Company issued pre-funded warrants to purchase up to 15,717,638 shares of common stock and issued three series of warrants to purchase up to 50,632,914 shares of common stock. In connection with these offerings, Wainwright received Placement Agent Warrants to purchase up to 1,012,658 shares of common stock. In connection with the Registered Direct Offering, the Company issued pre-funded warrants to purchase up to 3,105,000 shares of common stock, and in the concurrent Private Placement, the Company issued unregistered warrants to purchase up to 6,130,000 shares of common stock. The resale of the underlying shares of common stock were subsequently registered in July 2024 on Form S-1 (File No. 333-280927). In connection with these offerings, Wainwright received Placement Agent Warrants to purchase up to 367,800 shares of common stock. During the nine months ended September 30, 2024, all of the 1,668,236 pre-funded warrants issued in the October Registered Direct Offering were exercised at an exercise price of $ 0.001 per share, and all of the 18,822,638 pre-funded warrants issued in